Barr Wins Patent Challenge Vs. Ferring, Aventis

Law360, New York (February 9, 2005, 12:00 AM EST) -- Barr Laboratories, Inc. has won a patent challenge to the antidiuretic replacement therapy DDAVP (Desmopressin Acetate), a drug made by Ferring B.V. and Aventis Pharmaceuticals, Inc.

A judge with the U.S. District Court for the Southern District of New York granted summary judgment in Barr's challenge to the patents for DDAVP tablets, 0.1 mg and 0.2 mg, the company said.

The court ruled that the patents alleged to cover DDAVP are unenforceable and not infringed by Barr's product, according to Barr.

The court's decision effectively ends...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.